Immune Design Corporation Appoints Jan Henrik ter Meulen, M.D., Chief Scientific Officer
10/1/2013 9:39:24 AM
SEATTLE and SAN FRANCISCO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced the appointment of Jan Henrik ter Meulen, M.D., Dr. habil., DTM&H, as its Chief Scientific Officer.
Help employers find you! Check out all the jobs and post your resume.